Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4584180 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1a-Monotherapy Dose Escalation (Cohort A1) | EXPERIMENTAL | LY4584180 monotherapy administered orally |
| Phase 1a-Monotherapy Dose Optimization (Cohort A2) | EXPERIMENTAL | LY4584180 monotherapy administered orally |
| Phase 1b-Dose Expansion-Monotherapy (Cohort B1-B3) | EXPERIMENTAL | LY4584180 monotherapy administered orally |
| Phase 1b-Dose Expansion-Combination (Cohort B4) | EXPERIMENTAL | LY4584180 administered orally in combination with rituximab administered through IV infusion |
| Name | Type | Description |
|---|---|---|
| LY4584180 | DRUG | administered orally |
| Rituximab | DRUG | administered through IV infusion |
Inclusion Criteria: * Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy: * Diffuse large B-cell lymphoma - not otherwise specified * High-grade B-cell lymphoma * Diffuse large B-cell lymphoma - t...
LY4584180 is an investigational small molecule being studied for the treatment of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma. It is intended for adult participants with previously treated blood cancers. The drug is currently in Phase 1 clinical development.
LY4584180 is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting clinical research on this investigational oncology drug for the treatment of certain blood cancers.
LY4584180 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 study is recruiting participants to evaluate the drug in adults with previously treated blood cancers.
LY4584180 is being studied in a Phase 1 clinical trial identified as NCT07226843. This trial is recruiting 460 participants with non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, or follicular lymphoma. The study is enrolling adults aged 18 years and older across multiple countries.
Yes, LY4584180 is being evaluated in a controlled clinical trial. The Phase 1 study NCT07226843 uses a control group, though it is not randomized or double-blinded. The trial is actively recruiting participants in the United States, France, Germany, Italy, Japan, Poland, Spain, and the United Kingdom.